United Therapeutics (NASDAQ:UTHR) CFO Sells $5,401,500.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,195,871.40. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

James Edgemond also recently made the following trade(s):

• On Monday, June 22nd, James Edgemond sold 8,750 shares of United Therapeutics stock. The stock was sold at an average price of $538.15, for a total transaction of $4,708,812.50.
• On Monday, June 15th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.17, for a total transaction of $5,491,700.00.
• On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00.
• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total value of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total value of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total value of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.

United Therapeutics Price Performance

Shares of UTHR opened at $549.66 on Thursday. The company has a market cap of $23.33 billion, a P/E ratio of 20.29, a PEG ratio of 1.80 and a beta of 0.57. The stock has a fifty day moving average price of $562.63 and a 200 day moving average price of $525.08. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the business earned $6.63 earnings per share. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on UTHR. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in United Therapeutics in the second quarter worth approximately $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its position in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.